Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $35 million, down 5% year-over-year but up 2% sequentially from Q3 2025 [17] - Adjusted EBITDA for Q4 was $8.7 million, with an Adjusted EBITDA margin of approximately 25% [18] - Total Recurring Contract Value (TRCV) reached $144.1 million, up 8% year-over-year and marking the fifth consecutive quarter of sequential TRCV growth [17][18] - Full-year revenue for 2025 was $137.4 million, down 4% from 2024, with an Adjusted EBITDA of $40.2 million, representing a 29% margin [19] Business Line Data and Key Metrics Changes - New sales increased by 86% year-over-year, reflecting a successful sales team reorganization and refined coverage model [5] - The company achieved the highest gross dollar retention rate in over seven years, indicating strong customer engagement and retention efforts [5] Market Data and Key Metrics Changes - NRC Health serves 74% of the top 100 health systems in the U.S., showcasing its strong market presence and trust among healthcare leaders [9] - The company has a Net Promoter Score of 68, reflecting positive customer satisfaction and loyalty [9] Company Strategy and Development Direction - The company is focused on deepening adoption of enablement solutions and product innovation, with AI playing a significant role in enhancing capabilities [13][15] - NRC Health aims to expand its addressable market through strategic acquisitions and by leveraging its unique operating model to drive efficiencies [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to create lasting value, emphasizing the importance of trust, expertise, and a broad portfolio in navigating the complex healthcare landscape [24] - The company anticipates that revenue growth will follow the TRCV growth observed in 2025, positioning itself well for future profitability [19] Other Important Information - The company paid a quarterly dividend of $0.12 per share, reflecting its commitment to returning capital to shareholders [18] - NRC Health has made strategic leadership hires to support its growth initiatives, including the appointment of David Burik to lead strategic insights and governance [6][8] Q&A Session Summary - No specific questions or answers were provided in the content, indicating that the call concluded without a Q&A segment [25]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $35 million, down 5% year-over-year but up 2% sequentially from Q3 2025 [17] - Adjusted EBITDA for Q4 was $8.7 million, with an adjusted net income of $3.4 million and adjusted EPS of 16 cents per share [18] - Full year 2025 revenue was $137.4 million, down 4% from 2024, but TRCV grew by 8% in 2025, indicating potential revenue growth in 2026 [19] Business Line Data and Key Metrics Changes - Total Recurring Contract Value (TRCV) reached $144 million, up 8% year-over-year, marking the fifth consecutive quarter of sequential TRCV growth [4][17] - New sales increased by 86% year-over-year, reflecting effective sales strategies and customer engagement [5] Market Data and Key Metrics Changes - NRC Health serves 74% of the top 100 health systems in the U.S., indicating strong market presence and trust [9] - The company reported a Net Promoter Score of 68, reflecting high customer satisfaction [9] Company Strategy and Development Direction - The company is focused on enhancing its product portfolio and customer engagement strategies to drive growth [5][12] - Investment in AI and product innovation is a strategic priority to deepen differentiation and expand the addressable market [13] - The leadership team has been strengthened to support growth, with a focus on combining healthcare operations expertise with technology [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to create lasting value amidst the complexities of the healthcare landscape [24] - The company anticipates that the restructuring of its go-to-market strategy will provide a meaningful tailwind through 2026 [12] Other Important Information - The company maintained a disciplined approach to capital allocation, balancing investments in growth with returns to shareholders through dividends and share repurchases [21][22] - The adjusted EBITDA margin for 2025 was 29%, showcasing strong profitability despite revenue decline [19] Q&A Session Summary - No specific questions or answers were provided in the content, indicating a focus on the presentation rather than an interactive Q&A session.

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $35 million, down 5% year-over-year but up 2% sequentially from Q3 2025 [16] - Adjusted EBITDA for Q4 was $8.7 million, with an adjusted net income of $3.4 million and adjusted EPS of 16 cents per share [17] - Full year 2025 revenue was $137.4 million, down 4% from 2024, but TRCV grew by 8% in 2025, indicating potential revenue growth in 2026 [18] Business Line Data and Key Metrics Changes - Total Recurring Contract Value (TRCV) reached $144 million, marking an 8% year-over-year increase and the fifth consecutive quarter of sequential growth [4][16] - New sales increased by 86% year-over-year, reflecting effective sales strategies and customer engagement [5] Market Data and Key Metrics Changes - NRC Health serves 74% of the top 100 health systems in the U.S., indicating strong market presence and trust [9] - The company reported a Net Promoter Score of 68, showcasing high customer satisfaction [9] Company Strategy and Development Direction - The company is focused on enhancing its product portfolio and customer engagement strategies to drive growth [5][12] - Investment in AI and product innovation is a strategic priority to deepen differentiation and expand the addressable market [13] - The leadership team has been strengthened to support growth, with new hires bringing extensive healthcare experience [6][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to create lasting value amidst the complexities of the healthcare landscape [22] - The company anticipates that the restructuring of its go-to-market strategy will provide a meaningful tailwind for growth in 2026 [12] Other Important Information - The company maintained a disciplined approach to expense management while investing in growth initiatives, achieving a 29% adjusted EBITDA margin [18][19] - A quarterly dividend of 12 cents per share was paid, reflecting confidence in the financial profile [17] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.